Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: CellCept, Myfortic, Generic mycophenolate mofetil, Generic mycophenolate sodium
Mycophenolate is an immunosuppressant drug primarily used to prevent organ rejection after transplantation. It works by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo purine synthesis pathway, which is crucial for the proliferation of lymphocytes (white blood cells that play a central role in the immune response). By suppressing lymphocyte proliferation, mycophenolate reduces the immune system's ability to attack the transplanted organ. It exists in various forms including mycophenolate mofetil (MMF) and mycophenolate sodium (MPS).
Prevention of organ rejection following kidney, heart, and liver transplants.
Mycophenolate increases the risk of infections, including opportunistic infections and lymphomas. Patients receiving mycophenolate are at increased risk of developing pure red cell aplasia (PRCA). Mycophenolate can cause fetal harm and loss when administered to a pregnant woman. Mycophenolate is contraindicated in patients with hypersensitivity to the drug.
Outcome:
Increased acyclovir levels
Mechanism:
Competition for renal tubular secretion
Outcome:
Reduced mycophenolate absorption
Mechanism:
Binding of mycophenolate in the gut
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effects on gastric mucosa
Most likely new formulation: Extended-release mycophenolate mofetil (2025, 80% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for mycophenolate in autoimmune diseases within the next 5 years.
Immunosuppressant, Antimetabolite, IMPDH Inhibitor
Morpholinoethyl ester of mycophenolic acid (MMF), Sodium salt of mycophenolic acid (MPS)